(Q34128373)

English

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

Ana Maria Gonzalez-Angulo

5

object named as

Ana M Gonzalez-Angulo

1 reference

Europe PubMed Central

31 July 2017

Gabriel N Hortobagyi

6

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

31 July 2017

author name string

Catherine M Kelly

1

1 reference

Europe PubMed Central

31 July 2017

Savitri Krishnamurthy

2

1 reference

Europe PubMed Central

31 July 2017

Giampaolo Bianchini

3

1 reference

Europe PubMed Central

31 July 2017

Jennifer K Litton

4

1 reference

Europe PubMed Central

31 July 2017

Lajos Pusztai

7

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

116

1 reference

Europe PubMed Central

31 July 2017

22

1 reference

Europe PubMed Central

31 July 2017

5161-5167

1 reference

Europe PubMed Central

31 July 2017

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Commercialized multigene predictors of clinical outcome for breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Systematic review: gene expression profiling assays in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

The influence of a gene expression profile on breast cancer decisions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Development of the 21-gene assay and its application in clinical practice and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Primary systemic chemotherapy of invasive lobular carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25269

21 January 2018

Identifiers

10.1002/CNCR.25269

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34128373&oldid=1606500595"